| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Third Arc Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $197.75M | Series A | 7/16/2024 | $165M | $305.43M | $2.10 | Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs, BVF Partners, T. Rowe Price Associates, Janus Henderson Investors, abrdn, Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures | ||||
 | Alloplex Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $20.67M | Series A | 1/27/2023 | $20.67M | $279.9M | $68.60 | Undisclosed Investors | ||||
 | Ansa Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $57.42M | Series B Plus | 10/1/2025 | $24.28M | $260.65M | $0.35 | Cerberus Ventures, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fall Line Capital, AIM13, Black Opal Ventures | ||||
 | Ansun Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $165.2M | Series B | 8/15/2018 | $100M | $466.82M | $1.49 | Lilly Asia Ventures, Matrix Partners China, Yuanming Capital, Lyfe Capital, 3E Bioventures | ||||
 | Arine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $66.04M | Series C | 6/24/2025 | $30M | $494.87M | $15.42 | Town Hall Ventures, Kaiser Permanente Ventures | ||||
 | AZTherapies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.38M | Series C-1 | 8/28/2020 | $35M | $401.38M | $6.75 | Duopharma Biotech Berhad, Spinnaker Capital, ID Fund, DRADS Capital, Wexford Capital, Nextrans-KCLAVIS, Axiom Associates, DEFTA Partners | ||||
 | Biomeme | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $18.33M | Series Seed-1 | 4/11/2022 | $5.46M | $192.57M | $5.93 | Undisclosed Investors | ||||
 | Dispatch Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.79M | Series A | 7/23/2025 | $114M | $270.29M | $3.04 | ARCH Venture Partners, PICI, Bristol Myers Squibb, University of Pennsylvania, Stanford University, Alexandria Venture Investments | ||||
 | Elligo Health Research | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $213.37M | Series E-1 | 9/23/2021 | $34.87M | $392.04M | $1.99 | Morgan Stanley Expansion Capital, Ally Bridge Group, Norwest Venture Partners, Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler, Shumway Capital, Syneos Health | ||||
 | Ethyreal Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $150.00K | -- | 1 | Not available | -- | -- | $104.65M | Series B | 6/10/2026 | $60M | $353.63M | $4.43 | Avoro Capital, Atlas Venture, Medicxi Ventures, Nandi Life Sciences, Checkpoint Capital | ||||
 | Quanta Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series D | 6/24/2026 | $76.19M | $253.34M | $1.44 | Avidity Partners, Sofinnova Investments, Vida Ventures, Surveyor Capital, Longitude Capital, BVF Partners, AbbVie Ventures, GC&H Investments, WS Investment Company | ||||
 | Recludix Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $123.5M | Series B | 1/12/2026 | $21.5M | $327.7M | $2.31 | Access Biotechnology, Alexandria Venture Investments, NEA, Westlake Village BioPartners, Eli Lilly | ||||
 | Ring Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $229.04M | Series D | 3/4/2026 | $50M | $300.05M | $2.06 | Undisclosed Investors | ||||
 | Solve Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $296.39M | Series A | 11/17/2025 | $296.39M | $426.7M | $4.41 | Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, Matrix Capital Management, Decheng Capital, General Atlantic, Surveyor Capital | ||||
 | SynDevRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $52.6M | Series C | 9/30/2024 | $29.35M | $270.23M | $7.23 | Undisclosed Investors | ||||
 | Tenvie | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $200M | Series A | 1/8/2025 | $158.05M | $391.74M | $1.00 | ARCH Venture Partners, F-Prime Capital, Mubadala Capital | ||||
 | Tizona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $95.24M | Series B-3 | 1/3/2019 | $15M | $173.78M | $1.60 | AbbVie | ||||
 | Arcellx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.48M | Series C | 4/13/2021 | $120M | $377.76M | $2.10 | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | ||||
 | BioTheryX | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.09M | Series E | 5/20/2021 | $100M | $348.42M | $5.25 | Farallon Capital Management, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital management, Alexandria Ventur Investors, Wedbush Helthcare Partners | ||||
 | Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | ||||
 | Cullgen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $116M | Series C | 5/8/2023 | $35M | $264.09M | $2.63 | AstraZeneca-CICCVentureCapitalPartnership, SincereCapital, VoyagersCapital, WuxiCapitalGroup, GHIGroup | ||||
 | ElectraDx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $46.77M | Series B | 11/14/2025 | $32M | $270.54M | $7.31K | TAUNS Laboratories | ||||
 | Ensoma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.75M | Series B-1 | 7/2/2025 | $45.2M | $281.79M | $1.09 | Undisclosed Investors | ||||
 | Farcast Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $79.8M | Series B | 7/11/2018 | $73.28M | $153.24M | $0.35 | Northpond Ventures, Accel, Sequoia Capital, Sands Capital Ventures, RA Capital Management | ||||